Anakinra in COVID-19: important considerations for clinical trials

Andrew King; Andy Vail; Claire O'Leary; Cathal Hannan; David Brough; Hiren Patel; James Galea; Kayode Ogungbenro; Megan Wright; Omar Pathmanaban; Sharon Hulme; Stuart Allan

doi:10.1016/S2665-9913(20)30160-0

Anakinra in COVID-19: important considerations for clinical trials

Andrew King, Andy Vail, Claire O'Leary, Cathal Hannan, David Brough, Hiren Patel, James Galea, Kayode Ogungbenro, Megan Wright, Omar Pathmanaban, Sharon Hulme, Stuart Allan

Research output: Contribution to journal › Comment/debate › peer-review

12 Downloads (Pure)

Original language	English
Journal	The Lancet Rheumatology
Early online date	21 May 2020
DOIs	https://doi.org/10.1016/S2665-9913(20)30160-0
Publication status	Published - 1 Jul 2020

Access to Document

10.1016/S2665-9913(20)30160-0

anakinra draft revised cleanAccepted author manuscript, 39.2 KBLicence: CC BY-NC-ND

Cite this

@article{48f625f997fb45ae96678af6299575ba,

title = "Anakinra in COVID-19: important considerations for clinical trials",

author = "Andrew King and Andy Vail and Claire O'Leary and Cathal Hannan and David Brough and Hiren Patel and James Galea and Kayode Ogungbenro and Megan Wright and Omar Pathmanaban and Sharon Hulme and Stuart Allan",

year = "2020",

month = jul,

day = "1",

doi = "10.1016/S2665-9913(20)30160-0",

language = "English",

journal = "The Lancet Rheumatology",

issn = "2665-9913",

publisher = "Elsevier BV",

}

TY - JOUR

T1 - Anakinra in COVID-19: important considerations for clinical trials

AU - King, Andrew

AU - Vail, Andy

AU - O'Leary, Claire

AU - Hannan, Cathal

AU - Brough, David

AU - Patel, Hiren

AU - Galea, James

AU - Ogungbenro, Kayode

AU - Wright, Megan

AU - Pathmanaban, Omar

AU - Hulme, Sharon

AU - Allan, Stuart

PY - 2020/7/1

Y1 - 2020/7/1

U2 - 10.1016/S2665-9913(20)30160-0

DO - 10.1016/S2665-9913(20)30160-0

M3 - Comment/debate

JO - The Lancet Rheumatology

JF - The Lancet Rheumatology

SN - 2665-9913

ER -